Herantis Pharma Oyj (HRPMF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Herantis Pharma Oyj (HRPMF) with AI Score 44/100 (Weak). Herantis Pharma Oyj is a Finnish biotech company focused on developing disease-modifying therapies for Parkinson's disease. Their lead product candidates include HER-096 and rhCDNF. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Herantis Pharma Oyj (HRPMF) Healthcare & Pipeline Overview
Herantis Pharma Oyj, a Finnish biotechnology company, specializes in developing CDNF-based therapies for Parkinson's disease, with lead candidates HER-096 and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in preclinical and Phase I stages, respectively, positioning them in the competitive neurodegenerative disease treatment landscape.
Investment Thesis
Herantis Pharma Oyj presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on CDNF-based therapies for Parkinson's disease addresses a significant unmet medical need. Key value drivers include the successful advancement of HER-096 through preclinical development and positive results from the Phase I study of rhCDNF. The company's market capitalization is approximately $0.06 billion, and it currently has a negative P/E ratio of -6.84, reflecting its pre-revenue status. Growth catalysts include the progression of HER-096 into clinical trials and potential partnerships for further development and commercialization. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's small size and limited resources also pose challenges. Investors should carefully consider the inherent risks and uncertainties associated with biotechnology investments before investing in Herantis Pharma Oyj.
Based on FMP financials and quantitative analysis
Key Highlights
- Herantis Pharma Oyj is focused on developing disease-modifying therapies for Parkinson's disease (PD).
- The lead product candidate, HER-096, is in preclinical development as a potential treatment for PD and other neurodegenerative diseases.
- Recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) is in Phase I clinical study in patients with PD.
- The company's market capitalization is approximately $0.06 billion.
- Herantis Pharma Oyj has a negative P/E ratio of -6.84, reflecting its pre-revenue status.
Competitors & Peers
Strengths
- Proprietary CDNF-based technology platform.
- Lead product candidates targeting a significant unmet medical need.
- Experienced management team with expertise in drug development.
- Phase I clinical study underway for rhCDNF.
Weaknesses
- Limited financial resources.
- Small company size with limited infrastructure.
- Dependence on successful clinical trial outcomes.
- High risk associated with biotechnology investments.
Catalysts
- Upcoming: Interim data release from the Phase I clinical study of rhCDNF expected in late 2026.
- Upcoming: Potential initiation of Phase I clinical trials for HER-096 within the next 1-2 years, pending funding and regulatory approvals.
- Ongoing: Active pursuit of strategic partnerships for development and commercialization.
- Ongoing: Preclinical studies evaluating the efficacy of CDNF in other neurodegenerative diseases.
- Ongoing: Efforts to secure additional funding through grants, equity offerings, or debt financing.
Risks
- Potential: Clinical trial failures for HER-096 and rhCDNF.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from other companies developing Parkinson's therapies.
- Ongoing: Need for additional funding and potential dilution of existing shareholders.
- Potential: Limited financial resources and small company size.
Growth Opportunities
- Advancement of HER-096 into Clinical Trials: The successful progression of HER-096, the advanced small and synthetic chemical peptidomimetic version of xCDNF, into clinical trials represents a significant growth opportunity. Positive preclinical data suggest its potential as a disease-modifying therapy for Parkinson's. The timeline for initiating Phase I trials is projected within the next 1-2 years, contingent on securing funding and regulatory approvals. The market for effective Parkinson's treatments is estimated to reach $5.6 billion by 2027, offering a substantial commercial opportunity.
- Positive Results from rhCDNF Phase I Study: Positive outcomes from the ongoing Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) could serve as a major catalyst for growth. Demonstrating safety and preliminary efficacy in patients with Parkinson's disease would validate the CDNF-based approach and attract potential partners. Interim data is expected in late 2026, with final results anticipated in 2027. Success in this trial could lead to further clinical development and eventual commercialization.
- Strategic Partnerships for Development and Commercialization: Forming strategic partnerships with larger pharmaceutical companies or biotechnology firms could accelerate the development and commercialization of Herantis Pharma's pipeline. Collaborations could provide access to funding, expertise, and established distribution networks. The company is actively seeking potential partners, with discussions ongoing with several interested parties. A partnership agreement is anticipated within the next 12-18 months, which would significantly enhance the company's growth prospects.
- Expansion into Other Neurodegenerative Diseases: Leveraging the CDNF platform to develop therapies for other neurodegenerative diseases, such as Alzheimer's and Amyotrophic Lateral Sclerosis (ALS), represents a long-term growth opportunity. While Parkinson's disease is the primary focus, the potential of CDNF extends to other conditions characterized by neuronal damage and loss. Preclinical studies are underway to evaluate the efficacy of CDNF in these indications. Expansion into new therapeutic areas could significantly broaden the company's market reach and revenue potential.
- Securing Additional Funding to Support Pipeline Development: Securing additional funding through grants, equity offerings, or debt financing is crucial to support the continued development of Herantis Pharma's pipeline. The company requires significant capital to advance HER-096 into clinical trials and to continue the Phase I study of rhCDNF. The company is actively pursuing various funding options, with the goal of securing sufficient capital to fund its operations for the next 2-3 years. Successful fundraising would enable the company to execute its development plans and achieve key milestones.
Opportunities
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into other neurodegenerative diseases.
- Positive clinical trial results for HER-096 and rhCDNF.
- Securing additional funding to support pipeline development.
Threats
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other companies developing Parkinson's therapies.
- Need for additional funding and potential dilution of existing shareholders.
Competitive Advantages
- Proprietary CDNF-based technology platform.
- Intellectual property protection for HER-096 and rhCDNF.
- First-mover advantage in developing CDNF-based therapies for Parkinson's disease.
About HRPMF
Herantis Pharma Oyj, founded in 2008 and based in Espoo, Finland, is a biotechnology company dedicated to developing disease-modifying therapies for Parkinson's disease (PD). The company's primary focus is on harnessing the potential of Cerebral Dopamine Neurotrophic Factor (CDNF) to address the unmet needs in PD treatment. Their lead product pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate, and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical study in patients with PD. Herantis Pharma's strategy centers on creating innovative therapies that can protect and restore dopamine neurons, offering a potentially more effective approach compared to symptomatic treatments. The company is committed to advancing its pipeline through rigorous preclinical and clinical development, with the ultimate goal of providing transformative treatments for individuals affected by Parkinson's disease and other neurodegenerative conditions. The company operates primarily in Finland, focusing its research and development efforts on CDNF-based therapies.
What They Do
- Develop disease-modifying therapies for Parkinson's disease.
- Focus on Cerebral Dopamine Neurotrophic Factor (CDNF)-based therapies.
- Advance HER-096, a preclinical xCDNF candidate, for treating Parkinson's and other neurodegenerative diseases.
- Conduct Phase I clinical study of recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF) in Parkinson's patients.
- Research and develop innovative therapies to protect and restore dopamine neurons.
- Seek strategic partnerships for development and commercialization of their pipeline.
Business Model
- Develop and out-license novel therapeutics.
- Focus on unmet needs in Parkinson's disease treatment.
- Generate revenue through partnerships and potential future product sales.
Industry Context
Herantis Pharma Oyj operates within the competitive biotechnology industry, specifically targeting neurodegenerative diseases like Parkinson's. The market for Parkinson's disease treatments is substantial and growing, driven by an aging population and increasing prevalence. Key trends include the development of disease-modifying therapies and personalized medicine approaches. Competitors include companies like BioSpecifics Technologies Corp (BSTG), which focuses on collagenase-based therapies, and other firms developing novel treatments for neurological disorders. Herantis Pharma aims to differentiate itself through its CDNF-based approach, which has the potential to protect and restore dopamine neurons.
Key Customers
- Future patients with Parkinson's disease.
- Potential pharmaceutical partners.
- Healthcare providers treating neurodegenerative diseases.
Financials
Chart & Info
Herantis Pharma Oyj (HRPMF) stock price: Price data unavailable
Latest News
No recent news available for HRPMF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HRPMF.
Price Targets
Wall Street price target analysis for HRPMF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HRPMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Antti Vuolanto D.Sc. (Tech)
Chief Executive Officer
Antti Vuolanto holds a D.Sc. (Tech) degree and has extensive experience in the biotechnology industry. His background includes leadership roles in various pharmaceutical and biotech companies, where he focused on drug development, clinical trials, and commercialization strategies. He has a proven track record of successfully advancing drug candidates through the development pipeline and securing regulatory approvals. Vuolanto's expertise spans across multiple therapeutic areas, with a particular emphasis on neurodegenerative diseases.
Track Record: Since becoming CEO of Herantis Pharma Oyj, Antti Vuolanto has focused on advancing the company's pipeline of CDNF-based therapies for Parkinson's disease. He has overseen the progression of HER-096 into preclinical development and the ongoing Phase I study of rhCDNF. Under his leadership, the company has also sought strategic partnerships to accelerate development and commercialization. Vuolanto has successfully managed the company's limited resources and secured funding to support its operations.
HRPMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for trading on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. These securities often carry a higher degree of risk due to the lack of regulatory oversight and transparency compared to securities listed on major exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure requirements.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining accurate and timely information.
- Limited regulatory oversight and investor protection.
- Verify the company's registration and legal status.
- Review available financial information, if any.
- Assess the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and technology.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Company's incorporation in Finland, a country with strong corporate governance standards.
- Focus on developing therapies for a serious medical condition (Parkinson's disease).
- Ongoing Phase I clinical study for rhCDNF.
- CEO with relevant experience and qualifications.
- Presence of intellectual property protection for key assets.
Herantis Pharma Oyj Stock: Key Questions Answered
What does Herantis Pharma Oyj do?
Herantis Pharma Oyj is a biotechnology company focused on developing disease-modifying therapies for Parkinson's disease. The company's core technology revolves around Cerebral Dopamine Neurotrophic Factor (CDNF), a naturally occurring protein that protects and restores dopamine neurons. Their lead product candidates include HER-096, a preclinical xCDNF candidate, and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), which is currently in Phase I clinical study. The company aims to provide innovative treatments that address the underlying causes of Parkinson's disease, offering a potential improvement over existing symptomatic therapies.
What do analysts say about HRPMF stock?
As of 2026-03-17, there is no readily available analyst consensus on HRPMF stock due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio (-6.84), reflect the company's pre-revenue status and ongoing investment in research and development. Growth considerations center on the successful advancement of HER-096 and rhCDNF through clinical trials and potential partnerships. Investors should conduct their own thorough research and consider the inherent risks associated with biotechnology investments before making any decisions regarding HRPMF stock.
What are the main risks for HRPMF?
The main risks for Herantis Pharma Oyj include the inherent uncertainties associated with biotechnology drug development. Clinical trial failures for HER-096 and rhCDNF could significantly impact the company's prospects. Regulatory hurdles and delays in obtaining approvals also pose a risk. Competition from other companies developing Parkinson's therapies could limit market share. The company's limited financial resources and small size present additional challenges. Securing additional funding is crucial, and potential dilution of existing shareholders is a concern. Investors should carefully assess these risks before investing in HRPMF.
What are the key factors to evaluate for HRPMF?
Herantis Pharma Oyj (HRPMF) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary CDNF-based technology platform.. Primary risk to monitor: Potential: Clinical trial failures for HER-096 and rhCDNF.. This is not financial advice.
How frequently does HRPMF data refresh on this page?
HRPMF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HRPMF's recent stock price performance?
Recent price movement in Herantis Pharma Oyj (HRPMF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary CDNF-based technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HRPMF overvalued or undervalued right now?
Determining whether Herantis Pharma Oyj (HRPMF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HRPMF?
Before investing in Herantis Pharma Oyj (HRPMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis pending for HRPMF.